Study Design

LIBTAYO dosing protocol ¹

Treatment may be continued until symptomatic
disease progression or unacceptable toxicity.

In patients with a low body weight, a dose of 3 mg/kg every two weeks administered as an IV infusion over 30 minutes may be considered.

No dose reductions are recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability.

Please see the Product Monograph for completing dosing and administration recommendations.

IV: intravenous.

Libtayo is a clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles
Discard the vial if the solution is cloudy, discolored or contains extraneous particulate matter other than trace amounts of translucent-to-white particles
Do not shake the vial

Do not shake the solution
The final concentration of the diluted solution should be between 1 mg/mL to 20 mg/mL

LIBTAYO is for single use only. Dispose of any unused medicinal product or waste material in accordance with local requirements.

No compatibility studies have been performed. Do not mix with other medicinal products.

Once prepared, administer the diluted solution immediately. If diluted solution is not administered immediately, it may be stored temporarily either:

At room temperature up to 25°C for no more than 8 hours from the time of preparation. This includes room temperature storage of the infusion solution in the IV container and time for administration of the infusion.

Under refrigeration at 2°C to 8°C for no more than 24 hours from the time of infusion preparation. Allow the diluted solution to come to room temperature prior to administration.